Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.

1 Apr 2026

"Smart" system distinguishes and neutralizes cancer cells with unprecedented precision

A team from UNIGE has designed a molecular system that distinguishes and neutralizes cancer cells with unprecedented precision, paving the way for autonomous, self-regulating drugs.

1 Apr 2026

Advocate Health embraces drone technology for faster patient service

Advocate Health announced Thursday it will launch the nation's largest hospital-based drone delivery network, transforming how many of its patients receive prescriptions and home health supplies, while also reducing turnaround time for lab results, which are vital to timely diagnosis and treatment.

31 Mar 2026

Machine learning helps predict risks during stem cell therapy for myeloma

Multiple myeloma is a cancer in which plasma cells, which normally produce antibodies, multiply uncontrollably in the bone marrow.

31 Mar 2026

How the nutrient cysteine controls cancer-fighting power of T cells

A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Bloomberg School of Public Health have discovered how the immune system's CD8+ T cells use the nutrient cysteine to control two essential functions that compete for this resource - the immune cell's ability to multiply and its ability to kill cancer cells.

31 Mar 2026

Researchers identify markers of lymphoma recurrence

Follicular Lymphoma (FL) is a type of blood cancer and a form of non-Hodgkin's lymphoma. Thanks to new treatment breakthroughs, about 80% of FL patients have a survival rate of more than 10 years.

31 Mar 2026

Gene signature maps cholangiocarcinoma subtypes for precision treatment

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly concealed and heterogeneous nature.

31 Mar 2026

Genomic study advances prioritization of variants in cancer diagnostics

Hiroshima University researchers have developed a practical framework to identify candidate pathogenic variants hidden among the large number of variants of uncertain significance (VUS) detected in comprehensive genomic profiling (CGP) of cancers.

31 Mar 2026

New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma

The 1,341-gene signature for intrahepatic cholangiocarcinoma offers a framework for precise diagnosis and tailored therapies, addressing tumor heterogeneity.

From BGI Genomics 31 Mar 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

Study reveals ALDH2 vulnerability in APC-deficient colorectal cancer

A precision cancer strategy that selectively kills tumour cells while leaving healthy tissue intact may be within reach for the majority of colorectal cancer patients, according to new research published in Genes & Disease.

30 Mar 2026

PSMA therapy may postpone hormone treatment in prostate cancer patients

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is also effective in an earlier stage of the disease.

30 Mar 2026

UMGCCC awarded $3 million to train the next generation of oncology researchers

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has been awarded a prestigious $3 million National Cancer Institute (NCI) Career Development Award to train the next generation of oncology researchers focused on treating patients of all backgrounds.

27 Mar 2026

Industry and academic leaders gather to accelerate new cancer cures

Damon Runyon scientists and industry partners gathered on Tuesday, March 24, for the 2026 Accelerating Cancer Cures Research Symposium, hosted by Amgen in Cambridge, Massachusetts.

27 Mar 2026

LDCT screening significantly reduces lung cancer mortality in non-smokers

New evidence from a Chinese cohort presented today at the European Lung Cancer Congress (ELCC) 2026 shows that onetime lowdose computed tomography (LDCT) screening can significantly reduce lung cancer mortality in a non-risk based population, including individuals with no smoking history.

27 Mar 2026

Microfluidic chips enable realistic modeling of tumor immune environments

The challenge is that the tumor immune microenvironment is not a static backdrop but a constantly shifting ecosystem shaped by cancer cells, immune cells, stromal cells, cytokines, and physical barriers.

26 Mar 2026

Study reveals how inflammation disrupts lymph node structure in lymphoma

In aggressive lymphomas, inflammatory messengers reprogram the "conductors" of the immune system, causing lymph nodes structure to collapse.

26 Mar 2026

Can AI chatbots help brain tumor patients understand their care?

Integrating LLMs in brain tumor care could enhance patient understanding, but requires strict oversight to manage risks and ensure reliable information.

26 Mar 2026

Study links androgens to aggressive childhood brain tumor growth

An international team led by researchers at Baylor College of Medicine, Texas Children's Hospital, McGill University and University of Pittsburgh School of Medicine has discovered what drives the growth of a lethal pediatric brain tumor called Posterior Fossa Type A (PFA) ependymoma.

25 Mar 2026

New guidance aims to standardize tumor mutational burden in cancer

Immune checkpoint inhibitors have transformed cancer care, yet only a minority of patients respond to monotherapy, and immune-related adverse events remain a major concern.

25 Mar 2026